header-medias

Presse release

Porsolt, GlioCure, and the University Hospital of Angers, will join forces in the “Glio Preclinical Solutions (GPS)”, collaborative project to develop new and innovative models for the evaluation of first- and best-in class innovative cancer therapies for

Angers and Le Genest-Saint-Isle, France – GlioCure, a biopharmaceutical company specializing in...

Defymed and GlioCure initiate a collaboration in the field of solid tumors without therapeutic options

Strasbourg and Angers - Defymed, a Strasbourg-based medical technology company,...

GlioCure strengthens its management team with the recruitment of Dr. Sandrine Courtès as Director of Preclinical Development and Intellectual Property

GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the arrival of Dr....

GlioCure expands its know-how and technological offer to nanovectors

Angers – GlioCure SA, a biotechnology company specializing in neuro-oncology,...

GlioCure transforms into a Limited Liability Company and closes a new round of financing

Angers, April 13th, 2021 – GlioCure, a preclinical-drug-development company...

GlioCure finalises its seed capital with a financing from « French Tech Seed » and reports a second consecutive profitable year.

Angers, May 12th, 2020 – GlioCure SAS, a biotech company specialised in neuro-oncology,...

RELIEF, a strategic project for GlioCure, selected by EUREKA!

Angers, France - GlioCure SAS, a biotechnology company specialized in neuro-oncology,...

GlioCure receives the "Seal of Excellence" from the European Commission

GlioCure was awarded the "Seal of Excellence" under the H2020 Instrument PME phase 1 scheme for...

Merck Awards Grants to Biotechs Tackling Cancer and Cardiovascular Disease

Three European companies to use Merck’s Advance Biotech Grant prizes to accelerate...

An eminent oncologist joins the GlioCure Scientific and Medical Advisory Board

Dr. Jean-Pierre BIZZARI, world renowned expert in oncology, is joining GlioCure's Scientific and...